cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Omega Therapeutics
5 own
4 watching
Current Price
$3.12
$0.14
(4.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
447.34M
52-Week High
52-Week High
11.98000
52-Week Low
52-Week Low
2.69000
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization447.34M
icon52-Week High11.98000
icon52-Week Low2.69000
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Omega Therapeutics do?
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature s operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Omega Therapeutics make?
News & Events about Omega Therapeutics.
Zolmax
5 months ago
Omega Therapeutics, Inc. (NASDAQ:OMGA Get Rating) Director Richard A. Young sold 5,000 shares of the firms stock in a transaction on Thursday, April 6th. The shares were sold at an average price of $8.00, for a total value of $40,000.00. Following the sale, the director now directly owns 749,118 ...
Ticker Report
6 months ago
Omega Therapeutics (NASDAQ:OMGA Get Rating) and Biogen (NASDAQ:BIIB Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst ...
Zolmax
6 months ago
Omega Therapeutics, Inc. (NASDAQ:OMGA Get Rating) major shareholder Flagship Pioneering Inc. bought 3,323,310 shares of Omega Therapeutics stock in a transaction dated Monday, February 27th. The stock was acquired at an average cost of $5.78 per share, with a total value of $19,208,731.80. Following...
Ticker Report
6 months ago
Omega Therapeutics, Inc. (NASDAQ:OMGA Get Rating) major shareholder Flagship Pioneering Inc. bought 3,323,310 shares of Omega Therapeutics stock in a transaction dated Monday, February 27th. The stock was acquired at an average cost of $5.78 per share, with a total value of $19,208,731.80. ...
PR Newswire
11 months ago
Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform PR Newswire CAMBRIDGE, Mass., Oct. 17, 2022 Dr. Khrer has more than 25 years of RNA research and development experience, including pioneering novel...
Frequently Asked Questions
Frequently Asked Questions
What is Omega Therapeutics share price today?
plus_minus_icon
Can Indians buy Omega Therapeutics shares?
plus_minus_icon
How can I buy Omega Therapeutics shares from India?
plus_minus_icon
Can Fractional shares of Omega Therapeutics be purchased?
plus_minus_icon
What are the documents required to start investing in Omega Therapeutics stocks?
plus_minus_icon
What is today’s traded volume of Omega Therapeutics?
plus_minus_icon
What is today’s market capitalisation of Omega Therapeutics?
plus_minus_icon
What is the 52-Week High and Low Range of Omega Therapeutics?
plus_minus_icon
What percentage is Omega Therapeutics down from its 52-Week High?
plus_minus_icon
What percentage is Omega Therapeutics up from its 52-Week Low?
plus_minus_icon
Current Price
$3.12
$0.14
(4.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00